FindTrial
Sign In

Blastic plasmacytoid dendritic cell neoplasm in Korean population

Blastic plasmacytoid dendritic cell neoplasm in Korean population: A multicenter study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0003990
Enrollment
40
Registered
2019-05-27
Start date
2019-04-30
Completion date
Unknown
Last updated
2020-09-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Samsung Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Eligibility Criteria 1. Patients = 18 years 2. Pathologically confirmed diagnosis by tissue or bone marrow at each center with - Blastic plasmacytoid dendritic cell neoplasm - Blastic NK-cell lymphoma - Agranular CD4+ natural killer cell leukaemia - Blastic natural killer leukaemia/lymphoma - Agranular CD4+CD56+ haematodermic neoplasm/tumour 3. Antigen expression of CD4 and/or CD56 coupled with at least one plasmacytoid dendritic cell-associated antigen among CD123, TCL1, CD2AP and BDCA2/CD303

Exclusion criteria

Exclusion criteria: < Exclusion criteria > 1. Acute myeloid leukemia 2. Acute lymphoblastic leukemia 3. Mixed phenotype acute leukemia 4. Any type of B- or T-/NK/T-cell lymphomas 5. Expression of lineage-specific markers for B cells (CD20, CD79a) T cells (CD3) Myeloid cells (myeloperoxidase) Monocytes (CD11c, CD163, lysozyme). CD34

Design outcomes

Primary

MeasureTime frame
Disease-free Survival Rate;overall survival rates;Therapeutic response rates—

Secondary

MeasureTime frame
Factors affecting overall survival : age, ECOG, Involving organs, Response to treatment, Treatment, Autologous transplantation/? Allogeneic transplantation—

Countries

Korea, Republic of

Contacts

Public ContactSeokjin KIM

Samsung Medical Center

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026